All news

Pfizer target raised to $40 despite trading above consensus

Alpha Vantage · Yahoo! Finance Canada · · AI-summarised by FinFlash

Argus raised its price target for Pfizer Inc. (PFE) to $40, maintaining a positive outlook on the pharmaceutical and biotech drug developer. The report highlights Pfizer's diverse product portfolio, including oncology, immunology, rare disease treatments, and vaccines. This upgrade comes as senior analyst David H. Toung continues to cover the healthcare sector.

Read original source

PFE company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.